Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Lift your strategic role in climate, sustainability and ESG
By collaborating more closely with sustainability teams and using data-driven insights, risk professionals can shape resilience and help protect lon
Getting ahead of cancer
In this latest episode of our Inside Health series, Dr Zoe Williams sits down with Dr Tim Woodman, Bupa’s Medical Director of Policy, and Dr Frankie J
Theory to practice the first year of funding code valuations
In 2025, many defined benefit (DB) pension schemes faced a landmark moment: their first actuarial valuations under The Pensions Regulator’s (TPR’s) ne

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.